Tecemotide (L-BLP25) in Rectal Cancer

NCT01507103 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Rectal Cancer

Interventions

BIOLOGICAL: Tecemotide (L-BLP25)
DRUG: cyclophosphamide (CPA)
OTHER: Chemoradiotherapy

Sponsor

Merck KGaA, Darmstadt, Germany